ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ensysce Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.50−0.02 (-2.97%)
Close on Oct 19, 2026
- Market cap
- $6.56M
- P/E (TTM)
- –
- Dividend yield
- –
Ensysce Biosciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MPAR [Member] | $1.16M | $961.00K | $1.88M | $493.10K | $1.37M | $1.32M | $1.30M | $1.78M | – | – | $254.75K | $119.94K | 100.0% | -15.1% |
| TAAP/OUD [Member] | – | – | – | – | – | – | $0 | $1.64M | $181.80K | $305.72K | $260.28K | $315.44K | – | – |
By region
From the segment and revenue-disaggregation notes of Ensysce Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.